Determinants of generic and specific health-related quality of life in patients with Parkinson’s disease

Abstract

ObjectivesGeneric and disease-specific health-related quality of life (HRQoL) instruments may reflect different aspects of lives in patients with Parkinson’s disease (PD) and thus be associated with different determinants. We used the same cluster of predictors for the generic and disease-specific HRQoL instruments to examine and compare the determinants of HRQoL.MethodHRQoL was measured in 92 patients with PD by the 36-item Short-Form Health Survey (SF-36) and the 39-item Parkinson’s Disease Questionnaire (PDQ-39). The predictors included demographic and disease characteristics, and motor and non-motor symptoms. Multiple regression analyses were used to identify HRQoL determinants.ResultsDepressive symptoms and motor difficulties of daily living were the first two significant determinants for both instruments. The other significant determinant for the SF-36 was fatigue and non-motor difficulties of daily living, and for the PDQ-39 was motor signs of PD.ConclusionsThe results suggest the importance of the evaluation and intervention focused on depressive symptoms and motor difficulties of daily living in patients with PD. In addition, the SF-36 seems more related to non-motor symptoms, while the PDQ-39 appears more associated with motor symptoms. This information is important for understanding results from these two instruments and for choosing which to use.

Non-Motor Symptoms as Predictors of Quality of Life in Egyptian Patients With Parkinson’s Disease: A Cross-Sectional Study Using a Culturally Adapted 39-Item Parkinson’s Disease Questionnaire

“…Stigma was associated with younger age of enrollment, younger age of disease onset, disease severity, impaired daily activities and cognition, as well as depression. This is consistent with prior studies ( 32 , 33 ). Furthermore, it was correlated with fatigue/memory, mood/cognition domains, and total NMSS scores.…”

Fatigue in Parkinson's disease: A systematic review and meta‐analysis

“…Demographic features, disease severity, cognitive impairment, and depression did not exert significant effects on prevalence estimates. Following Barone and colleagues, we contrasted studies on de novo (five of 44 studies) versus studies on treated PD patients in which the same scale was used (28 studies). This contrast did not show differences in fatigue prevalence between treated and de novo PD patients (Table ).…”

Assessment of Hearing Impairment in Parkinson's Disease: Implications for Differential Diagnosis and Disease Progression

“…Four PD patients and one ART were not included in our data analysis because of middle ear disease revealed by the acoustic impedance test The PD group, by history, showed a mean disease duration of 8.7 ± 1.1 years and, on clinical examination, a mean UPDRS III score of 9.64 ± 5.6 (range, [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19], H&Y staging ranged from 1.5 to 3 (mean 2.4 ± 1.2).…”

“…More importantly, this finding further supports the dopaminergic origin of the hearing dysfunction observed in the PD group of interest. Hearing loss is significantly associated with depression and cognitive decline [4,18], which are two of the main NMS affecting the quality of life of PD patients [19] and therefore deserve an accurate picture in the clinical setting.…”